Institution de Lavigny Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2011
NCT01370486
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Institution de Lavigny

Active Ingredients

Drugs in Phase 4 Trials (1)

melatonin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lennox Gastaut Syndrome (Phase 4)

Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1